#USA #London #Drug Development #Clarivate #OFF-X

Clarivate Introduces Pathway Maps for Enhanced Drug Safety Assessments

Clarivate Plc, a global leader in transformative intelligence, is embarking on an innovative journey by enhancing its OFF-X platform. This cutting-edge translational safety intelligence solution now incorporates Pathway Maps that aim to revolutionize how researchers assess safety during drug development. With the significant challenges that come with safety liabilities, the integration of these maps stands to drastically improve target selection processes.

The stark reality of drug development's many hurdles is evident—over 30% of drug development failures can be traced back to safety issues. This statistic emphasizes the urgency that research and development (R&D) teams experience to identify potential risks early in their efforts. The introduction of Pathway Maps equips these teams with powerful visual interpretations that elucidate the biological mechanisms associated with diseases and their interactions with drug targets.

In traditional settings, collecting safety data can often be fragmented, leading to significant delays in critical decision-making activities. Clarivate's addition of Pathway Maps allows researchers to explore tailored visual representations of specific diseases, showcasing vital signaling pathways alongside curated safety data drawn from multiple sources. This enhanced insight facilitates more rapid and informed risk assessments by enabling users to identify potential liabilities swiftly, thus adding crucial biological context to their analyses.

Anne Lecocq, the Senior Vice President and General Manager of R&D in Life Sciences and Healthcare at Clarivate, stated, "The ability to assess the safety of drug targets early in development is crucial for minimizing costly late-stage failures while speeding up time to market. At Clarivate, we're committed to equipping our customers with advanced tools that streamline workflows and deliver in-depth insights aimed at improving patient outcomes and fostering a healthier future. The introduction of Pathway Maps into OFF-X marks a pivotal shift, merging complex biological data with safety intelligence, thus empowering researchers to make faster, more accurate, and data-driven choices."

OFF-X is not just a standalone tool; its integration of proprietary physiological and disease pathway visualizations with curated safety intel enhances risk evaluation. This convergence represents a major advancement, as it centralizes critical data access, assuring researchers that they are making well-informed decisions that lead to improved mitigation strategies.

The release of OFF-X underscores its commitment to supporting researchers at every stage of the drug development lifecycle—from initial discovery phases through to post-marketing surveillance. This platform merges the insights from OFF-X with Cortellis Drug Discovery Intelligence, leading to a comprehensive approach that addresses both efficacy and safety seamlessly.

In summary, Clarivate's OFF-X platform, further bolstered by Pathway Maps, presents a unique and robust solution for the intricate world of drug safety assessments. By streamlining accessibility to crucial safety insights tied directly to biological data, it allows researchers to tackle the inherent risks of drug development with renewed confidence. As the quest for innovative medicines continues, having accurate, data-driven insights is essential for success in this complex landscape.

For more information on Clarivate and the updated OFF-X platform, you can visit their website at clarivate.com.